North and Central Texas Clinical and Translational Science Initiative (KL2)

我们建议在德克萨斯州北部和中部建立一个诊所， 和转化科学倡议（NCTCTSI），这将是由得克萨斯大学领导 西南医学院在达拉斯，并将包括许多国家的领先学校， 对抗疗法和骨病医学，牙科，护理，药学，公共卫生，工程和 计算机科学-已经形成了一个高度功能性的关系， 路线图K12奖。我们已经建立了一个临床科学部，这是由 来自所有参与学校的教师，这将作为我们的CTSA的学术家园。的 部门提供学术任命的临床和翻译研究人员一起， 教师的专业知识和研究集中在方法学科共同的所有临床 研究-以促进多学科团队建设和解决问题。NCTCTSI将 以K30、M01和K12路线图奖支持的现有国家认可计划为基础 并将整合众多机构的优势，提供10个高度创新和完全集成的关键 职能：（1）教师招聘，发展和认可;（2）研究教育，培训和 职业发展;（3）研究计划的制定和支持;（4）科学审查和投资; (5)监管知识和支持;（6）参与者和临床互动资源;（7）新的 研究方法开发;（8）转化技术和资源;（9）生物医学信息学;（10）社区参与。特别的优势是：（1）实质性和 参与机构对倡议的明确承诺（已认捐约1.25亿美元 在未来五年内向NCTCTSI）;（2）一个既定的学术和文化家园，目前 解决NIH的许多目标;（3）> 200名已建立的临床和翻译研究人员， 将作为教师和导师;（4）一个高度创新的方法来整合关键职能，将采取行动 在多学科学术团体的成员之间建立联系;（5）一个庞大的， 医疗多样化的患者基础，由国际知名医院（实力雄厚） （6）每年为临床研究提供超过1.5亿美元的同行评审赠款支持; (7)一流的基础设施，以支持临床和转化研究;和（8）计划领导， 时间、经验和承诺，以确保该倡议的成功。配位合成 这些优势将使NCTCTSI能够为国家CTSA联盟做出贡献，从而帮助 确定最佳实践，将有利于全国各地的临床和转化研究。

We propose to establish a North and Central Texas Clinical and Translational Science Initiative (NCTCTSI), which will be led by the University of Texas Southwestern Medical School at Dallas and will include many of the nation's leading schools of allopathic and osteopathic medicine, dentistry, nursing, pharmacy, public health, engineering and computer science - which have already formed a highly functional relationship supported by a Roadmap K12 award. We have established a Department of Clinical Sciences, which is supported by faculty from all participating schools and which will serve as the academic home for our CTSA. The Department provides academic appointments to clinical and translational investigators together with faculty whose expertise and research is focused on methodological disciplines common to all clinical research - in order to promote multidisciplinary team building and problem solving. The NCTCTSI will build on existing nationally-recognized programs supported by K30, M01 and Roadmap K12 awards and will integrate numerous institutional strengths to offer 10 highly innovative and fully integrated key functions: (1) faculty recruitment, development and recognition; (2) research education, training and career development; (3) research plan development and support; (4) scientific review and investment; (5) regulatory knowledge and support; (6) participant and clinical interactions resources; (7) novel research methodology development; (8) translational technologies and resources; (9) biomedical informatics; and (10) community engagement. Particular strengths are: (1) the substantial and unequivocal commitment of participating institutions to the Initiative (which have pledged ~ $125 million to the NCTCTSI over the next five years); (2) an established academic and cultural home that currently address many of the goals of the NIH; (3) > 200 established clinical and translational investigators who will act as faculty and mentors; (4) a highly innovative approach to integrating key functions that will act to create bonds among the members of a multidisciplinary academic community; (5) a large and medically diverse patient base cared for by internationally-renowned hospitals (which are strong supporters of this initiative); (6) > $150 million in annual peer-reviewed grant support for clinical studies; (7) superb infrastructure to support clinical and translational research; and (8) program leadership with the time, experience and commitment to ensure the success of the Initiative. The coordinated synthesis of these strengths will allow the NCTCTSI to contribute to the national CTSA consortium and thus help to identify best practices that will benefit clinical and translational research throughout the nation.